Skip to main content
. Author manuscript; available in PMC: 2019 Sep 1.
Published in final edited form as: Neurourol Urodyn. 2019 Jul 8;38(7):1915–1923. doi: 10.1002/nau.24093

Table 3.

Side effects at 1- and 3 months. All p values comparing 1- and 3-month values were >0.05 and are not presented.

1 month 3 months
Side effect Overall
N=38
TUG <12
N=21
TUG ≥12
N=17
P value Overall
N=32
TUG <12
N=19
TUG ≥12
N=13
P value
Any side effect 28 (73.7) 17 (81) 11 (64.7) 0.26 27 (81.8) 17 (85.0) 10 (76.9) 0.56
Headache 5 (13.2) 1 (4.8) 4 (23.5) 0.09 6 (18.2) 3 (15.0) 3 (23.1) 0.56
Dry mouth 18 (47.4) 8 (38.1) 10 (58.8) 0.20 17(51.5) 9 (45.0) 8 (61.5) 0.35
Constipation 13 (34.2) 7 (33.3) 6 (35.3) 0.90 16 (48.5) 8 (40.0) 8 (61.5) 0.23
UTI 3 (7.9) 1 (4.8) 2 (11.8) 0.43 3 (9.1) 1 (5.0) 2 (15.4) 0.31
Nausea 5 (13.2) 1 (4.8) 4 (23.5) 0.09 6 (18.2) 3 (15.0) 3 (23.1) 0.56
Urinary retention 8 (21.1) 5 (23.8) 3 (17.6) 0.64 4 (12.1) 2 (10.0) 2 (15.4) 0.64
Fatigue 12 (32.4) 6 (28.6) 6 (37.5) 0.57 14 (42.4) 10 (50.0) 4 (30.8) 0.27
Confusion 7 (18.4) 3 (14.2) 4 (23.5) 0.46 5 (15.6) 2 (10.5) 3 (23.1) 0.34
Pain 6 (15.8) 2 (9.5) 4 (23.5) 0.24 9 (27.3) 6 (30.0) 3 (23.1) 0.66